Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Jennifer Trujillo to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Jennifer Trujillo has written about Diabetes Mellitus, Type 2.

 
Connection Strength
  
 
 
3.749
  
  1. Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
    View in: PubMed
    Score: 0.323
  2. Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020 11 17; 173(10):813-821.
    View in: PubMed
    Score: 0.280
  3. Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep; 45 Suppl 1:43-60.
    View in: PubMed
    Score: 0.280
  4. Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. J Diabetes Complications. 2020 04; 34(4):107520.
    View in: PubMed
    Score: 0.267
  5. Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018 11; 20(11):2690-2694.
    View in: PubMed
    Score: 0.243
  6. Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Ann Pharmacother. 2018 12; 52(12):1224-1232.
    View in: PubMed
    Score: 0.240
  7. Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018 May; 130(4):365-374.
    View in: PubMed
    Score: 0.236
  8. Trujillo JM, Goldman J. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy. 2017 Aug; 37(8):927-943.
    View in: PubMed
    Score: 0.226
  9. Goldman J, Trujillo JM. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2017 Nov; 51(11):990-999.
    View in: PubMed
    Score: 0.224
  10. Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017 Apr; 37(4):481-491.
    View in: PubMed
    Score: 0.219
  11. Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technol Ther. 2016 12; 18(12):749-758.
    View in: PubMed
    Score: 0.215
  12. Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Mar; 49(3):351-9.
    View in: PubMed
    Score: 0.189
  13. Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
    View in: PubMed
    Score: 0.187
  14. Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov; 48(11):1494-501.
    View in: PubMed
    Score: 0.184
  15. Trujillo JM, Barsky EE, Greenwood BC, Wahlstrom SA, Shaykevich S, Pendergrass ML, Schnipper JL. Improving glycemic control in medical inpatients: a pilot study. J Hosp Med. 2008 Jan; 3(1):55-63.
    View in: PubMed
    Score: 0.116
  16. Wright EE, Malone DC, Trujillo JM, Gill J, Huse S, Li X, Zhou FL, Preblick R, Reid T. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin. J Manag Care Spec Pharm. 2022 Jun; 28(6):592-603.
    View in: PubMed
    Score: 0.078
  17. Patel D, Triplitt C, Trujillo J. Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist. Adv Ther. 2019 05; 36(5):1031-1051.
    View in: PubMed
    Score: 0.063
  18. Anderson SL, Trujillo JM, Anderson JE, Tanenberg RJ. Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgrad Med. 2018 Mar; 130(2):229-238.
    View in: PubMed
    Score: 0.058
  19. Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015 Jan; 49(1):99-106.
    View in: PubMed
    Score: 0.047
  20. Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012 Jul-Aug; 52(4):466-71.
    View in: PubMed
    Score: 0.040
  21. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010 May; 44(5):904-9.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)